Correspondence 0001654954-23-016097 from FSD Pharma Inc. (QNTM) (CIK 0001771885) (QNTM)
FSD Pharma Inc. (QNTM) (CIK 0001771885)
Date: Dec. 29, 2023 · CIK: 0001771885 · Accession: 0001654954-23-016097
AI Filing Summary & Sentiment
File numbers found in text: 333-276264
Letter
fsd_corresp.htmFSD PHARMA INC.
199 Bay Street, Suite 4000
Toronto, Ontario M5L 1A9
December 29, 2023
Via EDGAR
Division of Corporation Finance
Office of Trade and Services
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:
FSD Pharma Inc.
Registration Statement on Form F-3 (File No. 333-276264)
Acceleration Request
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended (the “Act”), FSD Pharma Inc. (the “Company”), hereby requests that the effectiveness of the above-referenced Registration Statement on Form F-3 (the “Registration Statement”) be accelerated to, and that the Registration Statement become effective at 4:00 p.m. (Eastern Time) on January 4, 2024, or as soon thereafter as practicable. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
The Company hereby authorizes Daniel D. Nauth, an attorney with our outside legal counsel, Nauth LPC, to orally modify or withdraw this request for acceleration.
Please contact Daniel D. Nauth of Nauth LPC at (416) 477-6031 with any questions with respect to this request.
Sincerely,
FSD Pharma Inc.
Show Raw Text
CORRESP
1
filename1.htm
fsd_corresp.htmFSD PHARMA INC.
199 Bay Street, Suite 4000
Toronto, Ontario M5L 1A9
December 29, 2023
Via EDGAR
Division of Corporation Finance
Office of Trade and Services
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:
FSD Pharma Inc.
Registration Statement on Form F-3 (File No. 333-276264)
Acceleration Request
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended (the “Act”), FSD Pharma Inc. (the “Company”), hereby requests that the effectiveness of the above-referenced Registration Statement on Form F-3 (the “Registration Statement”) be accelerated to, and that the Registration Statement become effective at 4:00 p.m. (Eastern Time) on January 4, 2024, or as soon thereafter as practicable. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
The Company hereby authorizes Daniel D. Nauth, an attorney with our outside legal counsel, Nauth LPC, to orally modify or withdraw this request for acceleration.
Please contact Daniel D. Nauth of Nauth LPC at (416) 477-6031 with any questions with respect to this request.
Sincerely,
FSD Pharma Inc.
/s/Zeeshan Saeed
Zeeshan Saeed Chief Executive Officer
cc: Daniel D. Nauth, Nauth LPC